Merck returns drug rights to AVEO

Portfolio prioritization has caused Merck to return AV-299, an anti-hepatocyte growth factor antibody drug, to AVEO Pharmaceuticals. In June the developer initiated a Phase II trial of the drug, which triggered an $8.5 million milestone payment from Merck. Top-line efficacy data from the AV-299 Phase II trial are expected in late 2011. Release

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.